Genmab A/S
GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.97−0.99 (-1.91%)
Close on Nov 18, 2026
Genmab A/S R&D Employees at Period-End (FTEs): 2,081 in Q3 2026, up 13.0% from a year earlier.
Latest, Q3 2026
2,081
Period ended Sep 30, 2026
Change on a year earlier
+13.0%
1,841 in Q3 2025
History
30 quarters
Since Q1 2019
Sources
27
Documents cited below
Where the Q3 2026 figure comes from
“|| Research and development employees | $ | 2,081 | $ | 1,841”
Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
Consolidated research, translational medicine, CMC, and clinical development FTEs (64.1% of total workforce as of Q3 2026).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Genmab A/S R&D Employees at Period-End (FTEs), quarterly Q1 2019–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/fte-rd
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?